My message to the leaders assembling here in Munich is clear: global health security will never be a zero-sum game.

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

Climate-driven extreme weather disasters and resource conflicts can intensify social and political rifts both domestically ...

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...

Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...

GMG, a global retailer, manufacturer and distributor, has established itself as a dominant force in the retail industry ...

Major employers and innovators recognised at ceremony showcasing Ireland’s pharmaceutical leadership, as sector marks record ...

Sanofi has received China’s NMPA approval for the use of Sarclisa, combined with a standard-of-care regimen, for treating ...

Christian Leuprecht, political science professor at Queen's University and Royal Military College, says U.S. President Donald ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...